Type I osteogenesis imperfecta: a case report
Resumen
The term osteogenesis imperfecta includes several genetic defects of type I collagen, clinically traduced in bone fragility and deformity. The type I or Lobstein variety is the most frequent form of the disease and is characterized by a pattern of autosomal dominant inheritance. The case of a 65-year-old female patient, who came to our medical service at “Lucia Iñiguez Landin” Hospital of Holguin, Cuba, with multiple fractures after a slight fall was reported. She had short stature, a history of multiple fractures along her life, joint hypermobility, and blue grayish bulbar conjunctiva. Given the positive family history and the phenotypic assessment of the clinical picture, the patient was diagnosed with type I osteogenesis imperfecta. A detailed evaluation was carried out and the available medication was prescribed. The diagnostic and therapeutic update on this disease in Cuba is crucial for enhancing life quality of those who are affected.
Keywords: osteogenesis imperfecta, bone fragility and deformity, multiple fractures, diagnostic and therapeutic update
Referencias
Lindahl K, Åström E, Rubin CJ, Grigelioniene G, Malmgren B, Ljunggren Ö, et al. Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet.2015[cited 19/12/2019]; 23(8):1042-1050. Available at: https://www.nature.com/articles/ejhg201581
Lim J, Grafe I, Alexander S, Lee B. Genetic causes and mechanisms of osteogenesis imperfecta. Bone 2017. [Cited 19/12/2019]; 102:40-49. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607741/
Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. Osteoporos Int. 2016[cited 25/01/2020]; 27(12):3427-3437.Available at: http://publicationslist.org/data/frauch/ref-315/Trejo-2016-Osteogenesis%20imperfecta%20in%20children.pdf
Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; [cited 25/01/2020]; 16(2):101-116. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1012733/
Tournis S, Dede A. Osteogenesis imperfect-A clinical update. Metabolismo 2018 [cited 26/01/2020];80:27-37. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0026049517301580
Hernández García I, Fernández Martín M, León Pérez S, García García A, Riaño Echenique J. Osteogénesis imperfecta: mosaicismo germinal o evidencia de heterogeneidad genética. Presentación de una familia y revisión bibliográfica. Rev Cubana Pediatr. 2007[cited 26/01/20];79(3).Available at: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312007000300012
García OA, Rives GY, Álvarez BD. Embarazada con Osteogénesis Imperfecta tipo IV. Revista Cubana de Obstetricia y Ginecología. 2019; [cited 28/1/2020]; 45(1):66-73. Available at: http://revginecobstetricia.sld.cu/index.php/gin/article/view/90
Torres Molina A. Huesos de cristal .Presentación de un caso. Medisur 2010[cited 28/01/20];8(4). Available at: http://medisur.sld.cu/index.php/medisur/article/view/1057
Uttarilli A, Shah H, SriLakshmi Bhavani G, Upadhyai P, Shukla A, Girisha KM. Phenotyping and genotyping of skeletal dysplasias: Evolution of a center and a decade of experience in India. Bone. 2019[cited 04/02/2020];120:204-211. Available at: https://www.sciencedirect.com/science/article/abs/pii/S875632821830406X
Gil JA, DeFroda SF, Sindhu K, Cruz AI, Daniels AH. Challenges of Fracture Management for Adults with Osteogenesis Imperfecta. Orthopedics. 2017[cited 25/08/2020];40(1):17-22.Available at: https://journals.healio.com/doi/abs/10.3928/01477447-20161006-04
Vuorimies I, Mäyränpää MK, Valta H, Kröger H, Toiviainen Salo S, Mäkitie O. Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta. J Clin Endocrinol Metab. 2017[cited 04/02/2020];102(4):1333-1339.Available at: https://academic.oup.com/jcem/article/102/4/1333/2913385
Nicol L, Wang Y, Smith R, Sloan J,Cs Nagamani S, Shapiro J, et al. Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy. J Bone Miner Res. 2018[cited 25/08/2020];33(2):307-315 .Available at: https://asbmr.onlinelibrary.wiley.com/doi/full/10.1002/jbmr.3312
Hoyer Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, et al. Safety and efficacy of denosumab in children with osteogenesis imperfect-a first prospective trial. J Musculoskelet Neuronal Interact.2016[cited 04/02/2020]16(1):24-32.Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089451/
Copyright (c) 2021 David Armando Guach Hevia, Carlos Rafael Almira-Gómez
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.